Analysts Offer Predictions for ALLR FY2026 Earnings

Allarity Therapeutics, Inc. (NASDAQ:ALLR) – Analysts at Ascendiant Capital Markets raised their FY2026 earnings per share (EPS) estimates for Allarity Therapeutics in a research report issued to clients and investors on Saturday, June 6th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will post earnings per share of ($0.92) for the year, up from their previous forecast of ($0.96). Ascendiant Capital Markets has a “Buy” rating and a $10.25 price objective on the stock. The consensus estimate for Allarity Therapeutics’ current full-year earnings is ($0.96) per share. Ascendiant Capital Markets also issued estimates for Allarity Therapeutics’ Q1 2027 earnings at ($0.25) EPS.

Allarity Therapeutics (NASDAQ:ALLR) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.05. The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.03 million.

Several other research firms have also commented on ALLR. Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Monday, April 20th. Wall Street Zen raised Allarity Therapeutics to a “hold” rating in a research report on Saturday, May 30th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $10.25.

Allarity Therapeutics Price Performance

NASDAQ:ALLR opened at $1.49 on Thursday. The business’s 50-day moving average is $1.43 and its two-hundred day moving average is $1.21. Allarity Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.35. The firm has a market capitalization of $23.71 million, a PE ratio of -2.07 and a beta of 0.52.

Institutional Trading of Allarity Therapeutics

Large investors have recently modified their holdings of the business. Jane Street Group LLC acquired a new stake in shares of Allarity Therapeutics during the second quarter valued at about $27,000. XTX Topco Ltd acquired a new stake in shares of Allarity Therapeutics during the fourth quarter valued at about $36,000. Geode Capital Management LLC grew its stake in shares of Allarity Therapeutics by 49.3% during the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after acquiring an additional 16,729 shares in the last quarter. Capital Advisors Inc. OK acquired a new stake in shares of Allarity Therapeutics during the fourth quarter valued at about $108,000. Finally, DRW Securities LLC acquired a new stake in shares of Allarity Therapeutics during the fourth quarter valued at about $133,000. 11.53% of the stock is currently owned by institutional investors and hedge funds.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.